CN116102648A - 一种单域抗体或其抗原结合片段及其用途 - Google Patents
一种单域抗体或其抗原结合片段及其用途 Download PDFInfo
- Publication number
- CN116102648A CN116102648A CN202210835397.0A CN202210835397A CN116102648A CN 116102648 A CN116102648 A CN 116102648A CN 202210835397 A CN202210835397 A CN 202210835397A CN 116102648 A CN116102648 A CN 116102648A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- single domain
- amino acid
- domain antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title claims abstract description 30
- 230000027455 binding Effects 0.000 title abstract description 34
- 239000000427 antigen Substances 0.000 title abstract description 27
- 239000012634 fragment Substances 0.000 title abstract description 27
- 102000036639 antigens Human genes 0.000 title abstract description 26
- 108091007433 antigens Proteins 0.000 title abstract description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 60
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 11
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 239000000611 antibody drug conjugate Substances 0.000 claims description 15
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000003259 recombinant expression Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 241001416177 Vicugna pacos Species 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000562 conjugate Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- -1 gaseous Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 229940124675 anti-cancer drug Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 239000008299 semisolid dosage form Substances 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 108010055450 with HCG C-terminal peptide human follicle stimulating hormone Proteins 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 abstract description 8
- 238000003780 insertion Methods 0.000 abstract description 6
- 230000037431 insertion Effects 0.000 abstract description 6
- 238000012217 deletion Methods 0.000 abstract description 5
- 230000037430 deletion Effects 0.000 abstract description 5
- 230000035772 mutation Effects 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 17
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 17
- 229940028334 follicle stimulating hormone Drugs 0.000 description 17
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 10
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 10
- 238000004091 panning Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001817 pituitary effect Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002989 hypothyroidism Effects 0.000 description 4
- 208000003532 hypothyroidism Diseases 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003329 adenohypophysis hormone Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000000624 ovulatory effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 206010000217 Abortion incomplete Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 102220577005 C5a anaphylatoxin chemotactic receptor 1_Y14F_mutation Human genes 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000006630 Incomplete Abortion Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Reproductive Health (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
初次免疫 | 加强免疫1 | 加强免疫2 | 加强免疫3 | |
免疫时间 | 第0天 | 第21天 | 第42天 | 第63天 |
免疫剂量(mg) | 0.5 | 0.25 | 0.25 | 0.25 |
佐剂 | 弗氏不完全佐剂 | 弗氏不完全佐剂 | 弗氏不完全佐剂 | 弗氏不完全佐剂 |
免疫方式 | 皮下 | 皮下 | 皮下 | 皮下 |
SEQ ID NO: | EC50(ng/ml) | SEQ ID NO: | EC50(ng/ml) |
2 | 10.28 | 6 | 13.75 |
3 | 25.90 | 7 | 14.01 |
4 | 5.05 | 8 | 23.46 |
5 | 9.46 | 1G9E | N/A* |
Claims (29)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210835397.0A CN116102648A (zh) | 2021-09-07 | 2021-09-07 | 一种单域抗体或其抗原结合片段及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210835397.0A CN116102648A (zh) | 2021-09-07 | 2021-09-07 | 一种单域抗体或其抗原结合片段及其用途 |
CN202111045734.8A CN113698481B (zh) | 2021-09-07 | 2021-09-07 | 一种抗体或其抗原结合片段及其应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111045734.8A Division CN113698481B (zh) | 2021-09-07 | 2021-09-07 | 一种抗体或其抗原结合片段及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116102648A true CN116102648A (zh) | 2023-05-12 |
Family
ID=78659025
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210848964.6A Pending CN116375862A (zh) | 2021-09-07 | 2021-09-07 | 一种单域抗体或其抗原结合片段及其应用 |
CN202111045734.8A Active CN113698481B (zh) | 2021-09-07 | 2021-09-07 | 一种抗体或其抗原结合片段及其应用 |
CN202210835397.0A Pending CN116102648A (zh) | 2021-09-07 | 2021-09-07 | 一种单域抗体或其抗原结合片段及其用途 |
CN202210817818.7A Active CN115433276B (zh) | 2021-09-07 | 2021-09-07 | 一种vhh抗体或其抗原片段的突变体及其应用 |
CN202210831856.8A Pending CN115160436A (zh) | 2021-09-07 | 2021-09-07 | 高亲和力单域抗体或其抗原结合片段及其应用 |
CN202210832387.1A Pending CN115160437A (zh) | 2021-09-07 | 2021-09-07 | 一种抗体或其抗原结合片段及其应用 |
CN202210825845.9A Pending CN116063490A (zh) | 2021-09-07 | 2021-09-07 | 一种vhh抗体或其抗原片段的突变体及其用途 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210848964.6A Pending CN116375862A (zh) | 2021-09-07 | 2021-09-07 | 一种单域抗体或其抗原结合片段及其应用 |
CN202111045734.8A Active CN113698481B (zh) | 2021-09-07 | 2021-09-07 | 一种抗体或其抗原结合片段及其应用 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210817818.7A Active CN115433276B (zh) | 2021-09-07 | 2021-09-07 | 一种vhh抗体或其抗原片段的突变体及其应用 |
CN202210831856.8A Pending CN115160436A (zh) | 2021-09-07 | 2021-09-07 | 高亲和力单域抗体或其抗原结合片段及其应用 |
CN202210832387.1A Pending CN115160437A (zh) | 2021-09-07 | 2021-09-07 | 一种抗体或其抗原结合片段及其应用 |
CN202210825845.9A Pending CN116063490A (zh) | 2021-09-07 | 2021-09-07 | 一种vhh抗体或其抗原片段的突变体及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (7) | CN116375862A (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114316043B (zh) * | 2021-12-28 | 2022-09-20 | 三优生物医药(上海)有限公司 | 一种TGFβ1抗原结合分子及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102686609A (zh) * | 2009-10-23 | 2012-09-19 | 加文医学研究所 | 修饰的可变域分子及其生产和使用方法 |
WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
CN109081870B (zh) * | 2018-09-21 | 2021-12-03 | 成都阿帕克生物科技有限公司 | 一种抗人促绒毛膜促性腺激素β亚单位的纳米抗体及核酸分子和应用 |
-
2021
- 2021-09-07 CN CN202210848964.6A patent/CN116375862A/zh active Pending
- 2021-09-07 CN CN202111045734.8A patent/CN113698481B/zh active Active
- 2021-09-07 CN CN202210835397.0A patent/CN116102648A/zh active Pending
- 2021-09-07 CN CN202210817818.7A patent/CN115433276B/zh active Active
- 2021-09-07 CN CN202210831856.8A patent/CN115160436A/zh active Pending
- 2021-09-07 CN CN202210832387.1A patent/CN115160437A/zh active Pending
- 2021-09-07 CN CN202210825845.9A patent/CN116063490A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115160436A (zh) | 2022-10-11 |
CN113698481A (zh) | 2021-11-26 |
CN115160437A (zh) | 2022-10-11 |
CN115433276B (zh) | 2024-04-02 |
CN113698481B (zh) | 2022-09-20 |
CN115433276A (zh) | 2022-12-06 |
CN116375862A (zh) | 2023-07-04 |
CN116063490A (zh) | 2023-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI796328B (zh) | B7-h3抗體、其抗原結合片段及其醫藥用途 | |
JP4753578B2 (ja) | 合成抗体ファージライブラリー | |
TWI842707B (zh) | 最佳化抗-tl1a抗體 | |
CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
CN111057145A (zh) | 猪繁殖与呼吸综合征病毒Nsp2蛋白纳米抗体及其应用 | |
CN112661849B (zh) | 一种艰难梭菌重组蛋白单克隆抗体的制备方法和应用 | |
CN115433276B (zh) | 一种vhh抗体或其抗原片段的突变体及其应用 | |
CN114106187A (zh) | 一种靶向ogt的特异性鲨鱼单域抗体及其制备方法和应用 | |
CN109628410B (zh) | 一种鼠抗曲霉菌多糖杂交瘤细胞株,单克隆抗体及应用 | |
CN109609466B (zh) | 鼠抗曲霉菌多糖杂交瘤细胞株,单克隆抗体及应用 | |
WO2017198148A1 (zh) | 一种il-13抗体及其制备方法和应用 | |
WO2019096219A1 (zh) | 一种人源化抗il-13抗体及其制备方法和应用 | |
CN108635579B (zh) | 抗人bFGF纳米抗体在制备治疗黑色素瘤药物中的应用 | |
CN117164709B (zh) | 抗猪gsdmd蛋白单克隆抗体及其应用 | |
CN116948022B (zh) | 抗猪Gasdermin D蛋白单克隆抗体及其应用 | |
CN111065651B (zh) | Il-5抗体、其抗原结合片段及医药用途 | |
CN113150141B (zh) | 一种抗重组人碱性成纤维细胞生长因子纳米抗体及其应用 | |
WO2023279803A1 (zh) | Rbv的蛋白结合分子及其用途 | |
CN114057880B (zh) | 一种dll3单克隆抗体 | |
CN114539395B (zh) | SARS-CoV-2野生型毒株和α突变株骆驼源高亲和力纳米抗体 | |
CN114539394B (zh) | SARS-CoV-2α突变株和β突变株骆驼源高亲和力纳米抗体 | |
CN114702573A (zh) | 乙肝病毒表面s蛋白高亲和力纳米抗体及其应用 | |
TWI789679B (zh) | 抗人程序性死亡配體-1(pd-l1)的抗體及其用途 | |
TWI816616B (zh) | 抗人程序性死亡配體-1 (pd-l1) 的抗體及其用途 | |
WO2024061364A9 (zh) | 一种抗4-1bb纳米抗体及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240904 Address after: 215123 unit 301B, C13 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Applicant after: Suzhou Shengji Pharmaceutical Co.,Ltd. Country or region after: China Applicant after: Shanghai Baoji Pharmaceutical Co.,Ltd. Address before: Unit 301B, Floor C13, Bio-Nano Park, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000 Applicant before: Suzhou Shengji Pharmaceutical Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right |